CRIS Current Research Information System

TERRAGNA, CAROLINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.362
NA - Nord America 5.920
EU - Europa 3.995
AF - Africa 400
Continente sconosciuto - Info sul continente non disponibili 320
SA - Sud America 317
OC - Oceania 10
Totale 17.324
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.757
VN - Vietnam 1.894
CN - Cina 1.590
SG - Singapore 1.525
IT - Italia 1.057
GB - Regno Unito 692
DE - Germania 466
SE - Svezia 456
HK - Hong Kong 373
IN - India 266
FR - Francia 247
BR - Brasile 220
NL - Olanda 218
KR - Corea 191
RU - Federazione Russa 176
BD - Bangladesh 147
IE - Irlanda 135
CI - Costa d'Avorio 126
FI - Finlandia 116
JP - Giappone 91
UA - Ucraina 85
CA - Canada 79
TG - Togo 77
ZA - Sudafrica 76
CH - Svizzera 62
SC - Seychelles 55
AT - Austria 45
AR - Argentina 44
EE - Estonia 44
BG - Bulgaria 42
PH - Filippine 38
NG - Nigeria 36
PL - Polonia 36
TH - Thailandia 35
BE - Belgio 34
MX - Messico 31
JO - Giordania 29
ID - Indonesia 28
ES - Italia 23
TR - Turchia 22
TW - Taiwan 22
IR - Iran 21
IQ - Iraq 19
CO - Colombia 16
SA - Arabia Saudita 16
EC - Ecuador 15
JM - Giamaica 12
GR - Grecia 10
SV - El Salvador 10
RO - Romania 9
CZ - Repubblica Ceca 8
UZ - Uzbekistan 8
AU - Australia 7
CL - Cile 7
GT - Guatemala 7
LT - Lituania 7
HN - Honduras 6
PK - Pakistan 6
TT - Trinidad e Tobago 6
LB - Libano 5
TN - Tunisia 5
AL - Albania 4
CY - Cipro 4
DZ - Algeria 4
KE - Kenya 4
MA - Marocco 4
MY - Malesia 4
OM - Oman 4
PT - Portogallo 4
RS - Serbia 4
UY - Uruguay 4
CR - Costa Rica 3
EG - Egitto 3
HR - Croazia 3
HU - Ungheria 3
IL - Israele 3
PS - Palestinian Territory 3
PY - Paraguay 3
QA - Qatar 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
AZ - Azerbaigian 2
BS - Bahamas 2
ET - Etiopia 2
EU - Europa 2
GH - Ghana 2
GY - Guiana 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
MD - Moldavia 2
NI - Nicaragua 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PE - Perù 2
PR - Porto Rico 2
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
Totale 16.991
Salva come PNG Salva come JPEG
Città #
Singapore 1.050
Ashburn 732
Southend 582
Ho Chi Minh City 470
Chandler 460
Fairfield 380
Hefei 378
Hanoi 374
San Jose 364
Hong Kong 357
Bologna 241
Dallas 231
Ann Arbor 210
Beijing 202
Houston 184
Seoul 174
Seattle 163
Wilmington 163
Woodbridge 157
Dong Ket 151
Santa Clara 147
New York 144
Princeton 142
Dublin 135
Abidjan 126
Council Bluffs 126
Boardman 122
Cambridge 117
Los Angeles 101
Lauterbourg 94
Helsinki 89
Milan 80
Lomé 77
Tokyo 74
Bremen 65
Nanjing 62
Haiphong 56
Westminster 53
Frankfurt am Main 52
Munich 50
Rome 50
Padova 49
Bern 46
Da Nang 46
Hyderabad 46
São Paulo 43
Berlin 39
Buffalo 39
Sofia 39
Turin 39
Bengaluru 36
Guangzhou 35
Jacksonville 35
Jinan 35
Shenyang 34
Brussels 33
Redondo Beach 33
Tianjin 31
Abeokuta 30
Amman 29
Medford 29
Amsterdam 27
Toronto 26
Vienna 26
Biên Hòa 25
Changsha 24
Shanghai 24
Warsaw 24
Fabriano 23
Phoenix 23
Saint Petersburg 23
Redmond 22
Redwood City 22
San Diego 22
Nanchang 21
Zhengzhou 21
Chicago 20
Falkenstein 20
Johannesburg 20
London 20
Quận Bình Thạnh 20
Salsomaggiore Terme 20
Hebei 18
Ha Long 17
Jakarta 17
Nuremberg 17
Can Tho 16
Lappeenranta 16
Wuhan 16
Florence 15
Orem 15
San Francisco 15
Thái Nguyên 15
Washington 15
Atlanta 14
Dearborn 14
Montreal 14
Ninh Bình 14
Brooklyn 13
Chengdu 13
Totale 10.478
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 719
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles 335
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 273
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 272
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells 263
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 256
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 256
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 252
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 238
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 237
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 231
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 226
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 226
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 221
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 218
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 213
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 213
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 211
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 210
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 210
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 208
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 206
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 205
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 202
P-383 A 16-gene signature reflecting tumor microenvironment predicts the risk of multiple myeloma patients treated by bortezomib-based therapies 201
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 201
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 199
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 197
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 194
NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN THE DAILY CLINICAL MANAGEMENT OF PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS FEASIBLE AND PROVIDES USEFUL CLINICAL DATA. 194
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 192
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 188
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 184
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 182
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 181
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 180
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 178
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 177
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 176
Cap dependent translation contributes to resistance of myeloma cells to bortezomib 176
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) 176
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 173
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 172
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 172
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 171
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 169
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 167
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression 166
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 165
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 164
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 164
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 160
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 159
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 158
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 158
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 158
A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies 156
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 156
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 155
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 153
Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia 152
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 151
Association between genotypes and response to the treatment in a subset of previously untreated chronic myeloid leukemia patients enrolled into the TOPS trial. 147
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 146
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 146
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 144
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 143
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 142
Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib 142
Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging 138
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma 136
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation 135
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 134
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma 133
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 132
Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients. 131
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 130
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 130
New drugs to overcome meccanisms of resistance in Ph+ leukemia: Bosutinib 127
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 124
Molecular monitoring of acute myeloid leukemia associated with inv(16): Threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous complete remission is likely (multiple letters) [8] 121
COMPARISON BETWEEN NGS IGH/TCR AND RT-PCR BCR::ABL1 MINIMAL RESIDUAL DISEASE IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A PRELIMINARY ANALYSIS 119
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 115
Multiple myeloma: disease response assessment 113
Unraveling the Role of Peroxisome Proliferator-Activated Receptor β/Δ (PPAR β/Δ) in Angiogenesis Associated with Multiple Myeloma 112
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche 112
Primary pulmonary T-cell lymphoproliferative disorders with a limited-stage, low proliferative index, and unusual clinical behavior: two cases of a rare occurrence 106
Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies 99
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 97
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 94
Proteasome inhibitors: Bortezomib in multiple myeloma 94
Gene expression profiling (gep) of myeloma (MM) cells to predict attainment near complete response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed MM 93
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 92
Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment? 90
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 89
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 81
Identification of a novel large EPCAM-MSH2 duplication, concurrently with LOHs in chromosome 20 and X, in a family with Lynch syndrome 78
Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma 77
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives 66
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 65
Totale 17.049
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.254
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.254
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.327 0 67 64 98 135 83 30 100 69 163 232 286
2022/20231.969 189 286 76 297 149 146 64 104 298 63 158 139
2023/2024757 57 83 63 60 58 171 44 107 19 32 30 33
2024/20252.505 155 260 199 198 257 110 197 90 42 248 184 565
2025/20267.046 584 1.221 584 508 613 311 575 247 1.318 497 318 270
2026/2027474 186 288 0 0 0 0 0 0 0 0 0 0
Totale 17.324